4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸
|
|
|
- CAS號(hào):
- 1073612-91-5
- 英文名:
- CY-09
- 英文別名:
- CY-09;CS-2756;CY 09;CY09;CY09;CY 09;CY-09;CY-09, 10 mM in DMSO;CY-09,Inhibitor,NOD-like Receptor (NLR),inhibit,CY09;4-[[4-Oxo-2-thioxo-3-[3-(trifluoromethyl)benzyl]thiazolidin-5-ylidene]methyl]benzoic Acid;(E)-4-((4-oxo-2-thioxo-3-(3-(trifluoromethyl)benzyl)thiazolidin-5-ylidene)methyl)benzoic acid;4-[[4-Oxo-2-thioxo-3-[[3-(trifluoromethyl)phenyl]methyl]-5-thiazolidinylidene]methyl]benzoic acid;Benzoic acid, 4-[[4-oxo-2-thioxo-3-[[3-(trifluoromethyl)phenyl]methyl]-5-thiazolidinylidene]methyl]-
- 中文名:
- 4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸
- 中文別名:
- 化合物CY09;CY 09,NLRP3抑制劑;化合物CY09,10 MM DMSO 溶液;4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸;4-((4-氧代-2-硫代-3-(3-(三氟甲基)芐基)噻唑烷-5-亞基)甲基)苯甲酸
- CBNumber:
- CB43357761
- 分子式:
- C19H12F3NO3S2
- 分子量:
- 423.43
- MOL File:
- 1073612-91-5.mol
|
|
|
4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸化學(xué)性質(zhì)
-
儲(chǔ)存條件:
-
Store at -20°C
-
|
-
溶解度:
-
DMSO:65.0(Max Conc. mg/mL);152.61(Max Conc. mM)
-
|
-
形態(tài):
-
A crystalline solid
-
|
-
顏色:
-
Light yellow to yellow
-
|
-
InChI:
-
1S/C19H12F3NO3S2/c20-19(21,22)14-3-1-2-12(8-14)10-23-16(24)15(28-18(23)27)9-11-4-6-13(7-5-11)17(25)26/h1-9H,10H2,(H,25,26)/b15-9+
-
|
-
InChIKey:
-
DJTINRHPPGAPLD-OQLLNIDSSA-N
-
|
-
SMILES:
-
OC(C(C=C1)=CC=C1/C=C(SC2=S)\C(N2CC3=CC=CC(C(F)(F)F)=C3)=O)=O
-
|
4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸性質(zhì)、用途與生產(chǎn)工藝
CY-09是一種特異的NLRP3 inflammasome的抑制劑，直接靶向NLRP3。它對(duì)5種主要的cytochrome P450酶的IC50值分別為18.9, 8.18, >50, >50 和 26.0 μM。
| Target | Value |
NLRP3 inflammasome
()
|
CY-09 exhibits a dose-dependent inhibitory effect on monosodium urate (MSU), nigericin, ATP-induced caspase-1 activation and IL-1β secretion at the doses of 1 to10 μM in LPS-primed bone marrow-derived macrophages (BMDMs). Cytosolic LPS-induced noncanonical NLRP3 activation in BMDMs can also be blocked by CY-09 treatment. CY-09 specifically inhibits NLRP3 inflammasome activation and has no effect on LPS-induced priming effects. CY-09 treatment remarkably suppresses nigericin-induced ASC oligomerization. It is found that CY-09 treatment inhibits the interaction of Flag-NLRP3 and mCherry-NLRP3 in HEK-293T cells, suggesting that CY-09 blocks NLRP3 oligomerization.
CY-09 treatment
in vivo
efficiently suppresses monosodium urate (MSU) injection-induced IL-1β production and neutrophil influx, suggesting that CY-09 can block MSU-induced NLRP3 inflammasome activation
in vivo
. CY-09 treatment also increases the survival of
NLRP3
mutant mice up to days 30 to 48 even after treatment is stopped at day 25. The caspase-1 cleavage observed in adipose tissue of high-fat diet (HFD)-treated mice is also suppressed by CY-09.
4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸
上下游產(chǎn)品信息
上游原料
下游產(chǎn)品
| 更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS編號(hào) | 包裝 | 價(jià)格 |
|---|
| 2026/06/05 | HY-103666 | 4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸
CY-09 | 1073612-91-5 | 1mg | 660元 |
| 2026/06/05 | HY-103666 | 4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸
CY-09 | 1073612-91-5 | 5mg | 900元 |
4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸
生產(chǎn)廠家
4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸 圖譜信息:
1073612-91-5, 4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸 相關(guān)搜索:
- 抑制劑
- 合成有機(jī)化合物配體
- C19H12F3NO3S2
- 化合物CY09,10 MM DMSO 溶液
- CY 09,NLRP3抑制劑
- 化合物CY09
- 4-((4-氧代-2-硫代-3-(3-(三氟甲基)芐基)噻唑烷-5-亞基)甲基)苯甲酸
- 4-[[2-硫代-3-(3-三氟甲基芐基)-4-氧代噻唑烷-5-亞基]甲基]苯甲酸
- 1073612-91-5
- CY-09, 10 mM in DMSO
- CY-09,Inhibitor,NOD-like Receptor (NLR),inhibit,CY09
- Benzoic acid, 4-[[4-oxo-2-thioxo-3-[[3-(trifluoromethyl)phenyl]methyl]-5-thiazolidinylidene]methyl]-
- (E)-4-((4-oxo-2-thioxo-3-(3-(trifluoromethyl)benzyl)thiazolidin-5-ylidene)methyl)benzoic acid
- CY 09;CY09
- CY09;CY 09;CY-09
- 4-[[4-Oxo-2-thioxo-3-[[3-(trifluoromethyl)phenyl]methyl]-5-thiazolidinylidene]methyl]benzoic acid
- CS-2756
- 4-[[4-Oxo-2-thioxo-3-[3-(trifluoromethyl)benzyl]thiazolidin-5-ylidene]methyl]benzoic Acid
- CY-09